Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 26, 2024
Reporting Period: First nine months of 2024 (January 1, 2024 – September 30, 2024)
The filing incorporates a press release announcing financial results for the first nine months of 2024, highlighting global adoption of the ProSense® Cryoablation system.
Key Financial Metrics
- Sales Growth: 36% increase in sales for the first nine months of 2024 compared to the prior period.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific numerical values for revenue, net income, operating cash flow, gross margins, debt levels, or liquidity positions. It only references the percentage growth in sales.
Material Changes
The primary material change reported is a 36% year-over-year increase in sales for the nine-month period ended September 30, 2024. This growth is attributed to the global adoption of the Company's ProSense® Cryoablation technology.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the sales growth to the expanding global footprint of the ProSense® Cryoablation system.
Guidance and Outlook: The filing text does not contain specific forward-looking financial guidance or quantitative outlook projections.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the provided text of the Form 6-K.
Investor Verification Checklist
- Verify the absolute revenue figures for the first nine months of 2024 and the corresponding prior period to contextualize the 36% growth rate.
- Review the full press release (Exhibit 99.1) for details on gross margins, operating expenses, and net income, which are not included in this summary text.
- Confirm the specific geographic regions driving the "global adoption" of ProSense® Cryoablation.
- Check subsequent filings for updated liquidity positions and cash flow statements.